Clinical trial
A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer
NCT07608159 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Controlled, Multicenter Phase III Clinical Study of Spatially Fractionated Stereotactic Body Radiotherapy Plus Toripalimab and Chemotherapy Versus Toripalimab Plus Chemotherapy in Patients With Resectable or Potentially Resectable Stage II-III Non-Small Cell Lung Cancer
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- May 31, 2026
- Completion date
- May 31, 2030
- Enrollment
- 201 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
neoadjuvant chemoimmunotherapy, non small cell lung cancer, stereotactic body radiotherapy, surgery